{"id":"cvl237-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL942","moleculeType":"Small molecule","molecularWeight":"361.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, CVL237 tablets reduce glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes. CVL237 tablets have shown promise in phase 2 clinical trials for this indication.","oneSentence":"CVL237 tablets are a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:09:26.329Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07446049","phase":"PHASE2","title":"A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression","status":"NOT_YET_RECRUITING","sponsor":"Convalife (Shanghai) Co., Ltd.","startDate":"2026-05-01","conditions":"Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression","enrollment":180},{"nctId":"NCT06293716","phase":"PHASE2, PHASE3","title":"CVL237 Tablets for APDS/PASLI","status":"NOT_YET_RECRUITING","sponsor":"Convalife (Shanghai) Co., Ltd.","startDate":"2024-03-30","conditions":"PI3K and P110delta Hyperactivation Syndrome","enrollment":35},{"nctId":"NCT06183736","phase":"PHASE2","title":"CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Convalife (Shanghai) Co., Ltd.","startDate":"2023-12-20","conditions":"Advanced Solid Tumors","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CVL237 tablets","genericName":"CVL237 tablets","companyName":"Convalife (Shanghai) Co., Ltd.","companyId":"convalife-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CVL237 tablets are a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}